|
|
Exchange: |
Nasdaq Small Cap |
Security
Type: |
Common |
Shares
Out: |
15,080,000 |
Market
Cap: |
21.87(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$1.39 - $2.3 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Cumberland Pharmaceuticals is a pharmaceutical company engaged on the acquisition, development and commercialization of prescription products. Co.'s portfolio of brands include: Acetadote® (acetylcysteine) injection, for the treatment of acetaminophen poisoning; Caldolor® (ibuprofen) injection, for the treatment of pain and fever; Kristalose® (lactulose) for the treatment of constipation; Omeclamox®-Pak, (omeprazole, clarithromycin, amoxicillin) for the treatment of Helicobacter pylori infection and related duodenal ulcer disease; and Vaprisol® (conivaptan) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
19,352 |
Total Buy Value |
$0 |
$0 |
$0 |
$46,611 |
Total People Bought |
0 |
0 |
0 |
4 |
Total Buy Transactions |
0 |
0 |
0 |
324 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-04-04 |
2024-01-02 |
2023-07-04 |
2022-07-04 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Kazimi A J |
Chairman and CEO |
|
2021-10-14 |
4 |
AB |
$2.81 |
$42 |
D/D |
15 |
5,769,609 |
|
16% |
|
Galante Joseph C |
Director |
|
2021-10-14 |
4 |
AB |
$2.81 |
$399 |
D/D |
142 |
42,215 |
|
16% |
|
Krogulski Kenneth |
Director |
|
2021-10-14 |
4 |
AB |
$2.81 |
$239 |
D/D |
85 |
178,205 |
|
16% |
|
Cearnal Martin E |
Sr VP/Chief Commercial Officer |
|
2021-10-14 |
4 |
AB |
$2.81 |
$295 |
D/D |
105 |
172,719 |
|
16% |
|
Young Caroline |
Director |
|
2021-10-13 |
4 |
AB |
$2.71 |
$41 |
D/D |
15 |
13,808 |
|
10% |
|
Jones James |
Director |
|
2021-10-13 |
4 |
AB |
$2.71 |
$114 |
D/D |
42 |
17,556 |
|
10% |
|
Kazimi A J |
Chairman and CEO |
|
2021-10-13 |
4 |
AB |
$2.71 |
$41 |
D/D |
15 |
5,769,594 |
|
10% |
|
Galante Joseph C |
Director |
|
2021-10-13 |
4 |
AB |
$2.71 |
$385 |
D/D |
142 |
42,073 |
|
10% |
|
Krogulski Kenneth |
Director |
|
2021-10-13 |
4 |
AB |
$2.71 |
$230 |
D/D |
85 |
178,120 |
|
10% |
|
Cearnal Martin E |
Sr VP/Chief Commercial Officer |
|
2021-10-13 |
4 |
AB |
$2.71 |
$285 |
D/D |
105 |
172,614 |
|
10% |
|
Young Caroline |
Director |
|
2021-10-12 |
4 |
AB |
$2.71 |
$41 |
D/D |
15 |
13,793 |
|
12% |
|
Jones James |
Director |
|
2021-10-12 |
4 |
AB |
$2.71 |
$114 |
D/D |
42 |
17,514 |
|
12% |
|
Kazimi A J |
Chairman and CEO |
|
2021-10-12 |
4 |
AB |
$2.71 |
$41 |
D/D |
15 |
5,769,579 |
|
12% |
|
Galante Joseph C |
Director |
|
2021-10-12 |
4 |
AB |
$2.71 |
$385 |
D/D |
142 |
41,931 |
|
12% |
|
Krogulski Kenneth |
Director |
|
2021-10-12 |
4 |
AB |
$2.71 |
$230 |
D/D |
85 |
178,035 |
|
12% |
|
Cearnal Martin E |
Sr VP/Chief Commercial Officer |
|
2021-10-12 |
4 |
AB |
$2.71 |
$285 |
D/D |
105 |
172,509 |
|
12% |
|
Young Caroline |
Director |
|
2021-10-11 |
4 |
AB |
$2.73 |
$41 |
D/D |
15 |
13,778 |
|
13% |
|
Jones James |
Director |
|
2021-10-11 |
4 |
AB |
$2.73 |
$115 |
D/D |
42 |
17,472 |
|
13% |
|
Kazimi A J |
Chairman and CEO |
|
2021-10-11 |
4 |
AB |
$2.73 |
$41 |
D/D |
15 |
5,769,564 |
|
13% |
|
Galante Joseph C |
Director |
|
2021-10-11 |
4 |
AB |
$2.73 |
$388 |
D/D |
142 |
41,789 |
|
13% |
|
Krogulski Kenneth |
Director |
|
2021-10-11 |
4 |
AB |
$2.73 |
$232 |
D/D |
85 |
177,950 |
|
13% |
|
Cearnal Martin E |
Sr VP/Chief Commercial Officer |
|
2021-10-11 |
4 |
AB |
$2.73 |
$287 |
D/D |
105 |
172,404 |
|
13% |
|
Young Caroline |
Director |
|
2021-10-08 |
4 |
AB |
$2.84 |
$43 |
D/D |
15 |
13,763 |
|
14% |
|
Jones James |
Director |
|
2021-10-08 |
4 |
AB |
$2.84 |
$119 |
D/D |
42 |
17,430 |
|
14% |
|
Kazimi A J |
Chairman and CEO |
|
2021-10-08 |
4 |
AB |
$2.84 |
$43 |
D/D |
15 |
5,769,549 |
|
14% |
|
2379 Records found
|
|
Page 43 of 96 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|